Works (2)

Updated: July 5th, 2023 15:29

2019 journal article

Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin

Journal of Veterinary Internal Medicine, 33(2), 783–791.

By: B. Hallman n, M. Hauck n, L. Williams*, P. Hess n & S. Suter n

author keywords: canine; cardiology; cardiomyopathy; chemotherapy; echocardiography; oncology
MeSH headings : Animals; Antibiotics, Antineoplastic / administration & dosage; Antibiotics, Antineoplastic / adverse effects; Antibiotics, Antineoplastic / therapeutic use; Body Weight; Cardiomyopathy, Dilated / veterinary; Cardiotoxicity / veterinary; Dog Diseases / drug therapy; Dogs; Doxorubicin / administration & dosage; Doxorubicin / adverse effects; Doxorubicin / therapeutic use; Female; Heart Diseases / chemically induced; Heart Diseases / veterinary; Incidence; Male; Neoplasms / drug therapy; Neoplasms / veterinary; Retrospective Studies; Risk Factors
TL;DR: Overall, the incidence of clinical DOX‐induced cardiotoxicity is low, but Boxers and other breeds at high risk for dilated cardiomyopathy may be at an increased risk. (via Semantic Scholar)
Sources: Web Of Science, ORCID, NC State University Libraries, Crossref
Added: April 22, 2019

2017 journal article

The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma

Canadian Journal of Veterinary Research, 81(3), 199–205.

By: T. Gieger, J. Nettifee-Osborne, B. Hallman, C. Johannes, D. Clarke, M. Nolan, L. Williams

Source: NC State University Libraries
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.